Journal article

The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials

Michele Fornaro, Andre F Carvalho, Andrea Fusco, Annalisa Anastasia, Marco Solmi, Michael Berk, Kang Sim, Eduard Vieta, Andrea de Bartolomeis

Journal of Affective Disorders | ELSEVIER | Published : 2020


BACKGROUND: The definitions of treatment-resistant bipolar disorder (TRBD) have varied across studies. Additionally, its management is clinically challenging. An updated synthesis and appraisal of the available evidence is needed. METHODS: A systematic search of major electronic databases from inception up to May 25th, 2020, was conducted to identify randomized controlled trials (RCTs) of pharmacological and non-pharmacological interventions for the management of TRBD. When sufficient evidence was available, a meta-analysis was conducted. RESULTS: Seventeen studies (n = 928 patients) were included in the qualitative synthesis. Fourteen studies (n = 803) assessed treatment-resistant acute bip..

View full abstract

University of Melbourne Researchers


Awarded by National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship

Funding Acknowledgements

MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (APP1059660 and APP1156072).EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Sage, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), EU Horizon 2020, and the Stanley Medical Research Institute.AdB has received research support from Janssen, Lundbeck, and Otsuka and lecture honoraria from Chiesi, Lundbeck, Roche, Sunovion, and Takeda; he has served on advisory boards for Eli Lilly, Janssen, Lundbeck, Otsuka, Roche, and Takeda.